A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells
- Institution
- ORPHAGEN PHARMACEUTICALS, CA
- Principal investigator
- Scott Mcnear Thacher
- Funding
- $634K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
ABSTRACT Inflammatory bowel disease (IBD) is a lifelong inflammatory condition of the gut in which modulation of the immune system is the major therapeutic strategy. However, despite development of novel therapies, including antibodies to TNF and IL-12/IL-23p40, and inhibitors of T cell gut homing such as vedolizumab and ozanimod, only 30-50% of patients experience a sustained therapeutic benefit. Orphagen is developing first-in-class specific small molecule antagonists to the retinoic acid receptor-alpha (RAR) that regulate the induction of both the gut homing integrin 47 and a second gut homing receptor, CCR9, during T cell activation. Our preliminary data confirm that inhibition of retinoic acid signaling through RAR is a promising therapeutic approach to IBD. First, we showed that a probe RAR antagonist significantly improved gut histology in a mouse naïve T cell transfer colitis model and inhibited 47 expression and accumulation of inflammatory T cells in the colonic lamina propria of Citrobacter rodentium-infected mice. Second, with a more specific RAR lead antagonist, OR-812, an orally bioavailable new chemical entity designed at Orphagen, we showed in a mouse model of oral antigen stimulation that the induction of 47 and CCR9 in activated T cells is almost completely blocked at very low doses, <0.4 mg/kg; thus, antagonism of RAR by OR-812 potently blocks the induction of two key gut homing factors simultaneously. Third, OR-812 was well tolerated in a 14-day toxicity study in mice at 30 mg/kg following significant systemic exposure, indicating a strong safety margin for this new drug class. Our major objectives are to qualify OR-812 as a candidate for preclinical development, confirming efficacy in a murine model of colitis, scaling up sufficient compound for safety studies, and executing an exploratory safety study in a non-rodent species. In Aim 1, we evaluate the efficacy and potency of OR-812 in a mouse naïve T cell transfer colitis model. In Aim 2, we develop improved methods for synthesis of OR-812 and ultimately prepare a 500g batch for the non-rodent exploratory safety studies. In Aim 3, we identify a non-rodent species for in vivo toxicology studies based on in vitro metabolism of OR-812 in comparison to human and confirm adequate pharmacokinetics and bioavailability in the selected non-rodent species. In Aim 4, we conduct a 7-day maximum tolerated dose (MTD) safety study in the non-rodent species and, based on this, conduct a 14-day dose-range finding safety study in non-rodents with extensive assessment of target organ histopathology to determine the No Observed Adverse Effect Level (NOAEL). The overall goal of these non-GLP safety studies is to identify potential toxicities and confirm a preliminary safety margin for OR-812 based on the efficacious dose in a mouse colitis model. These investigations, if satisfactory, would prepare OR-812 for its next stage: regulated animal safety and chemical manufacturing studies appropriate for submission of an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for a novel drug class for treatment of IBD.
LOADING MOONBASE SCORE
Questions for Orphagen Pharmaceuticals
Orphagen Pharmaceuticals hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same topic, scored first.
- NIH · Univ of North Carolina Chapel HillNot yet scored
Immunologic and Microbial Mechanisms of Inflammatory Bowel Diseases Therapy Failure
Simon Matthew Gray · $172K · 2025–2030
- NIH · Rise Therapeutics, LlcNot yet scored
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
Gary Fanger · $705K · 2024–2027
- NIH · University of ArizonaNot yet scored
PARP1 and PARylation as novel effectors of gut inflammation
Fayez Khalaf Ghishan · $626K · 2023–2027